You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 296 No. 1, July 5, 2006 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Cardiovascular System
 •Cardiovascular Disease/ Myocardial Infarction
 •Drug Therapy
 •Drug Therapy, Other
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Medical Management of Peripheral Arterial Disease—Reply

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In Reply: Dr Hackam disagrees with our conclusion that aspirin is the preferred antiplatelet drug for PAD, citing randomized studies of clopidogrel1 and picotamide2 to suggest that these agents are more effective than aspirin. The CAPRIE trial was designed to compare the effectiveness and safety of clopidogrel and aspirin in patients at high vascular risk and showed that clopidogrel is marginally but significantly more effective than aspirin in preventing myocardial infarction, stroke, or death in all patients with high vascular risk (relative risk reduction [RRR], 8.7%; 95% CI, 0.3%-16.5%; P = .04). The study was not designed or powered to provide reliable conclusions about the effectiveness and safety of clopidogrel and aspirin in patients with PAD.

A subgroup analysis of CAPRIE did show that clopidogrel was more effective than aspirin in patients with PAD (RRR, 23.8%; 95% CI, 8.9%-36.2%; P = .003) but a test of heterogeneity of the treatment effects among . . . [Full Text of this Article]

John Eikelboom, MBBS, MSc
eikelbj@mcmaster.ca
Department of Medicine
McMaster University
Hamilton, Ontario

Graeme Hankey, MD
Department of Neurology
Royal Perth Hospital and School of Medicine and Pharmacology
Perth, Australia

Paul Norman, DS
School of Surgery and Pathology
University of Western Australia
Perth



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Medical Management of Peripheral Arterial Disease
Daniel G. Hackam
JAMA. 2006;296(1):41.
EXTRACT | FULL TEXT  

Medical Management of Peripheral Arterial Disease
Thomas E. Finucane
JAMA. 2006;296(1):41.
EXTRACT | FULL TEXT  

Medical Treatment of Peripheral Arterial Disease
Graeme J. Hankey, Paul E. Norman, and John W. Eikelboom
JAMA. 2006;295(5):547-553.
ABSTRACT | FULL TEXT  






HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.